Sanitas
Revista arbitrada de ciencias de la salud
Vol. 3(Especial odontología UNIANDES), 156-163, 2024
Efectos secundarios en pacientes que consumen Pregabalinas enfocadas en la Xerostomía
Side effects in patients taking Pregabalins targeting Xerostomia
Emmily Fernanda Tirira-Tana
Danny Mauricio Valverde-Cueltan
Dayelli Lisbeth Suárez-Moreta
Luigina Enriqueta Andrade-Burbano
162
REFERENCIAS
1. Millsop JW, Wang EA, Fazel N. Etiology, evaluation, and management of
xerostomia. Clin Dermatol. 2017;35(5):468-476.
doi:10.1016/j.clindermatol.2017.06.010
2. Tanasiewicz M, Hildebrandt T, Obersztyn I. Xerostomia of Various Etiologies: A
Review of the Literature. Adv Clin Exp Med. 2016;25(1):199-206.
doi:10.17219/acem/29375
3. Dreyer NS, Lynggaard CD, Jakobsen KK, Pedersen AML, von Buchwald C, Grønhøj
C. Ugeskr Laeger. 2021;183(27):V11200814.
4. Barbe AG. Medication-Induced Xerostomia and Hyposalivation in the Elderly:
Culprits, Complications, and Management. Drugs Aging. 2018;35(10):877-885.
doi:10.1007/s40266-018-0588-5
5. Gil-Montoya JA, Silvestre FJ, Barrios R, Silvestre-Rangil J. Treatment of xerostomia
and hyposalivation in the elderly: A systematic review. Med Oral Patol Oral Cir Bucal.
2016;21(3):e355-e366. Published 2016 May 1. doi:10.4317/medoral.20969
6. Thakkar JP, Lane CJ. Hyposalivation and Xerostomia and Burning Mouth Syndrome:
Medical Management. Oral Maxillofac Surg Clin North Am. 2022;34(1):135-146.
doi:10.1016/j.coms.2021.08.002
7. Paz C, Glassey A, Frick A, et al. Cancer therapy-related salivary dysfunction. J Clin
Invest. 2024;134(17):e182661. Published 2024 Sep 3. doi:10.1172/JCI182661
8. Grover SS, Rhodus NL. Xerostomia and Depression. Northwest Dent.
2016;95(3):29-35.
9. Agbo-Godeau S, Guedj A, Marès S, Goudot P. Sécheresse buccale (xérostomie)
[Xerostomia]. Presse Med. 2017;46(3):296-302. doi:10.1016/j.lpm.2017.02.004
10. Kim YJ. Xerostomia and Its Cellular Targets. Int J Mol Sci. 2023;24(6):5358.
Published 2023 Mar 10. doi:10.3390/ijms24065358
11. Ozasa K, Nishihara C, Watanabe K, et al. Somatosensory profile of a patient with
mixed connective tissue disease and Sjögren syndrome. J Am Dent Assoc.
2020;151(2):145-151. doi:10.1016/j.adaj.2019.09.001
12. Ramírez L, Sánchez I, Muñoz M, et al. Risk factors associated with xerostomia and
reduced salivary flow in hypertensive patients. Oral Dis. 2023;29(3):1299-1311.
doi:10.1111/odi.14090
13. Kim YJ. Xerostomia: Advances and Challenges in Drug Development. Curr Drug
Targets. 2024;25(5):301-305. doi:10.2174/0113894501293941240228050343
14. Gómez-Moreno G, Valerón-Rodríguez F. Pseudomembranous oral candidiasis
resolved with a mouthwash containing 0.05% chlorhexidine + 0.05% cetylpyridinium
chloride. Eur Rev Med Pharmacol Sci. 2021;25(18):5725-5728.
doi:10.26355/eurrev_202109_26790
15. Malallah OS, Garcia CMA, Proctor GB, Forbes B, Royall PG. Buccal drug delivery
technologies for patient-centred treatment of radiation-induced xerostomia (dry
mouth). Int J Pharm. 2018;541(1-2):157-166. doi:10.1016/j.ijpharm.2018.02.004